Cost effectiveness of golimumab for the treatment of active psoriatic arthritis

European Journal of Health Economics

Volumn 13, Issue 6, 2012, Pages 801-809

  Cummins, Ewen ^a   Asseburg, Christian ^b   Prasad, Manishi ^c   Buchanan, Jacqueline ^d   Punekar, Yogesh Suresh ^c  

^a McMaster Development Consultants   (United Kingdom)

^b Esior Oy   (Finland)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Buchanan Biotech Consulting   (United States)

Author keywords

Cost effectiveness; Golimumab; Psoriatic arthritis; TNF A inhibitor

Indexed keywords

ADALIMUMAB; ETANERCEPT; GOLIMUMAB; PLACEBO;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MALE; PALLIATIVE THERAPY; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870502013     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-011-0335-x     Document Type: Article

References (25)

1. Gladman, D.D., Antoni, C., Mease, P., Clegg, D.O., Nash, P.: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64(II), ii14-ii17 (2006)
2. Krueger, G.G.: Clinical features of psoriatic arthritis. Am. J. Manag. Care 8, S160-S170 (2002)
3. Gottleib, A., Korman, N.J., Gordon, K.B., et al.: Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. J. Am. Acad. Dermatol. 58, 851-864 (2008)
4. Helliwell, P.S.: Therapies for dactylitis in psoriatic arthritis. A systematic review. J. Rheumatol. 33, 1439-1441 (2006)
5. Mease, P.J.: Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. Semin. Arthritis Rheum. 38, 320-335 (2009)
6. TAG 104. Etanercept and infliximab for the treatment of adults with psoriatic arthritis. NICE technology appraisal guidance 104. July 2006:18
7. Williams, J.P., Meyers, J.A.: Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am. J. Manag. Care 8, S664-S681 (2002)
8. Huscher, D., Merkesdal, S., Thiele, K., Ziedler, H., Schneider, M., Zink, A.: Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematous in Germany. Ann. Rheum. Dis. 65, 1175-1183 (2006)
9. Mau, W., Listing, J., Huscher, D., Zeidler, H., Zink, A.: Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J. Rheumatol. 32, 721-728 (2005)
10. Wallenius, M., Skomsvoll, J.F., Koldingsnes, W., et al.: Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann. Rheum. Dis. 68, 685-689 (2009)
11. Kyle, S., Chandler, D., Griffiths, C.E.M., et al.: Guideline for anti-TNF-A therapy in psoriatic arthritis. Rheumatology 44, 390-397 (2005)
12. Kavanaugh, A.F., Ritchlin CT, GRAPPA Treatment Guideline Committee.: Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J. Rheumatol. 33, 1417-1421 (2006)
13. Kavanaugh, A., McInnes, I., Mease, P., et al.: Golimumab, a new human tumor necrosis factor-A antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis. Arthritis Rheum. 60, 976-986 (2009)
14. Cummins, E., Asseburg, C., Punekar, Y. et al.: Cost-effectiveness of infliximab for the treatment of active and progressive arthritis. Value in Health (2010)
15. Rogers, M., Epstein, D., Bojke, L., et al.: Etanercept, Infliximab and Adalimumab for the treatment of Psoriatic Arthritis: a systematic review and economic evaluation. Final Report 4th December 2009; Available at http://www.guidance.nice.org. uk/TA/WaveR/36
16. Woolacott, N., Bravo Vergel, Y., Hawkins, N., et al.: Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol. Assess. 10, 1-265 (2006)
17. Wong, K., Gladman, D.D., Husted, J., et al.: Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 40, 1868-1872 (1997)
18. Bravo Vergel, Y., Hawkins, N.S., Claxton, K., et al.: The costeffectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology 46, 1729-1735 (2007)
19. NICE TAG 199. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (review of technology appraisal guidance 104 and 125). NICE 2010. Available at http://www. nice.org.uk/nicemedia/live/13110/50422/50422.pdf accessed on 18th April 2011
20. Antoni, C., Krueger, G., de Vlam, K., et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64, 1150-1157 (2005)
21. Antoni, C.E., Kavanaugh, A., Kirkham, B.: Sustained benefits of infliximab therapy for dermatological and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. 4, 1227-1236 (2005)
22. Mease, P.J., Goffe, B.S., Metz, J., et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356, 385-390 (2000)
23. Mease, P.J., Kivitz, A.J., Burch, F.X., et al.: Etanercept treatment of psoriatic arthritis safety, efficacy, and effect on disease progression. Arthritis Rheum. 50(7), 2264-2272 (2004)
24. Mease, P.J., Gladman, D.D., Ritchlin, C.T., et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a randomised placebo controlled trial. Arthritis Rheum. 52(10), 3279-3289 (2005)
25. Genovese, M.C., Mease, P.J., Thomson, G.T., et al.: Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J. Rheumatol. 34(6), 1439 (2007)